Abonnement à la biblothèque: Guest
Critical Reviews™ in Oncogenesis

Publication de 4  numéros par an

ISSN Imprimer: 0893-9675

ISSN En ligne: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease Progression

Volume 25, Numéro 1, 2020, pp. 57-70
DOI: 10.1615/CritRevOncog.2020035667
Get accessGet access

RÉSUMÉ

The gut microbiome (GM) is a multifaceted environment wherein nearly 1014 microorganisms play various roles in host immune regulation, intestinal cell proliferation, bone mineralization, xenobiotics metabolism, and protection against pathogens. GM is also strongly coupled with the development and progression of nutrition-related diseases such as nonalcoholic fatty liver disease (NAFLD), wherein the gut-liver axis plays a major role as the gut and liver are functionally and anatomically associated through the portal vein. Dysbiosis causes leaky gut, resulting in the activation of inflammatory processes in the liver. Disruption of the gut barrier enhances microbial infiltration into the sub-mucosae, which through the bloodstream causes harmful microbial metabolites, such as butyrate, long-chain fatty acids, endotoxins, and indole-3-acetic acid, to seep into the liver. In NAFLD patients, these metabolites can lead to the development of nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC). In this review, we will discuss the important molecular pathways through which various metabolites and other signaling substances released by the GM regulate liver biology, under both physiological and pathological conditions. Finally, we highlight numerous therapeutic attempts, such as probiotics, prebiotics, and fecal microbial transplantation (FMT), to reprogram the gut-liver axis for decreasing liver diseases.

RÉFÉRENCES
  1. Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, Ferrell LD, Liu YC, Torbenson MS, Unalp-Arida A, Yeh M, McCullough AJ, Sanyal AJ. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005 Jun;41(6):1313-21. PubMed PMID: 15915461. Epub 2005/05/26.eng.

  2. Younossi ZM. Non-alcoholic fatty liver disease-a global public health perspective. J Hepatol. 2019 Mar;70(3):531-44. PubMed PMID: 30414863. Epub 2018/11/12.eng.

  3. Estes C, Razavi H, Loomba R, Younossi Z, Sanyal AJ. Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology. 2018 Jan;67(1): 123-33. PubMed PMID: 28802062. PMCID: PMC5767767. Epub 2017/08/13.eng.

  4. Kleiner DE, Makhlouf HR. Histology of Nonalcoholic Fatty liver disease and nonalcoholic steatohepatitis in adults and children. Clin Liver Dis. 2016 May;20(2):293-312. PubMed PMID: 27063270. PMCID: PMC4829204. Epub 2016/04/12.eng.

  5. Pais R, Barritt AS IV, Calmus Y, Scatton O, Runge T, Lebray P, Poynard T, Ratziu V, Conti F. NAFLD and liver transplantation: Current burden and expected challenges. J Hepatol. 2016 Dec;65(6): 1245-57. PubMed PMID: 27486010. PMCID: PMC5326676. Epub 2016/08/04.eng.

  6. Younossi Z, Anstee QM, Marietti M, Hardy T, Henry L, Eslam M, George J, Bugianesi E. Global burden of NAFLD and NASH: Trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018 Jan;15(1):11-20. PubMed PMID: 28930295. Epub 2017 Sep 20.

  7. Hossain N, Kanwar P, Mohanty SR. A comprehensive updated review of pharmaceutical and nonpharmaceutical treatment for NAFLD. Gastroenterol Res Pract. 2016;2016:7109270. PubMed PMID: 27006654. PMCID: PMC4781972. Epub 2016/03/24.eng.

  8. Mazzotti A, Caletti MT, Sasdelli AS, Brodosi L, Marchesini G. Pathophysiology of nonalcoholic fatty liver disease: Lifestylegut-gene interaction. Digest Dis. 2016;34(Suppl 1):3-10. PubMed PMID: 27548720. Epub 2016/08/23.eng.

  9. Koeckerling D, Tomlinson JW, Cobbold JF. Fighting liver fat. Endocrine Connections. 2020 Jul;9(7):R173-r86. PubMed PMID: 32621584. Epub 2020/07/06.eng.

  10. Chavez-Tapia NN, Uribe M, Ponciano-Rodriguez G, Medina-Santillan R, Mendez-Sanchez N. New insights into the pathophysiology of nonalcoholic fatty liver disease. Ann Hepatol. 2009;8(Suppl 1):S9-17. PubMed PMID: 19381119. Epub 2009/06/25.eng.

  11. Wu GD, Chen J, Hoffmann C, Bittinger K, Chen YY, Keilbaugh SA, Bewtra M, Knights D, Walters WA, Knight R, Sinha R, Gilroy E, Gupta K, Baldassano R, Nessel L, Li H, Bushman FD, Lewis JD. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011 Oct 7;334(6052):105-8. PubMed PMID: 21885731. PMCID: PMC3368382. Epub 2011/09/03.eng.

  12. Aron-Wisnewsky J, Clement K. The gut microbiome, diet, and links to cardiometabolic and chronic disorders. Nat Rev Nephrol. 2016 Mar; 12(3): 169-81. PubMed PMID: 26616538. Epub 2015/12/01.eng.

  13. Tilg H, Zmora N, Adolph TE, Elinav E. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2020 Jan;20(1):40-54. PubMed PMID: 31388093. Epub 2019/08/08.eng.

  14. Woodhouse CA, Patel VC, Singanayagam A, Shawcross DL. Review article: The gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease. Aliment Pharmacol Ther. 2018 Jan;47(2):192-202. PubMed PMID: 29083037. Epub 2017/10/31.eng.

  15. Wiest R, Albillos A, Trauner M, Bajaj JS, Jalan R. Targeting the gut-liver axis in liver disease. J Hepatol. 2017 Nov;67(5): 1084-103. PubMed PMID: 28526488. Epub 2017/05/21.eng.

  16. Ursell LK, Clemente JC, Rideout JR, Gevers D, Caporaso JG, Knight R. The interpersonal and intrapersonal diversity of human-associated microbiota in key body sites. J Allergy Clin Immunol. 2012 May;129(5):1204-8. PubMed PMID: 22541361. PMCID: PMC3342686. Epub 2012/05/01.eng.

  17. Leung C, Rivera L, Furness JB, Angus PW. The role of the gut microbiota in NAFLD. Nat Rev Gastroenterol Hepatol. 2016 Jul;13(7):412-25. PubMed PMID: 27273168. Epub 2016/06/09.eng.

  18. Kundu P, Blacher E, Elinav E, Pettersson S. Our gut microbiome: The evolving inner self. Cell. 2017 Dec 14;171(7): 1481-93. PubMed PMID: 29245010. Epub 2017/12/16.eng.

  19. Tremaroli V, Backhed F. Functional interactions between the gut microbiota and host metabolism. Nature. 2012 Sep 13;489(7415):242-9. PubMed PMID: 22972297. Epub 2012/09/14.eng.

  20. Shreiner AB, Kao JY, Young VB. The gut microbiome in health and in disease. Curr Opin Gastroenterol. 2015 Jan;31(1):69-75. PubMed PMID: 25394236. PMCID: PMC4290017. Epub 2014/11/14.eng.

  21. Hendrikx T, Schnabl B. Antimicrobial proteins: Intestinal guards to protect against liver disease. J Gastroenterol. 2019 Mar;54(3):209-17. PubMed PMID: 30392013. PM-CID: PMC6391196. Epub 2018/11/06.eng.

  22. Miele L, Marrone G, Lauritano C, Cefalo C, Gasbarrini A, Day C, Grieco A. Gut-liver axis and microbiota in NA-FLD: Insight pathophysiology for novel therapeutic target. Curr Pharm Design. 2013;19(29):5314-24. PubMed PMID: 23432669. Epub 2013/02/26.eng.

  23. Nagata K, Suzuki H, Sakaguchi S. Common pathogenic mechanism in development progression of liver injury caused by non-alcoholic or alcoholic steatohepatitis. J Toxicol Sci. 2007 Dec;32(5):453-68. PubMed PMID: 18198478. Epub 2008/01/17.eng.

  24. Odenwald MA, Turner JR. The intestinal epithelial barrier: A therapeutic target? Nat Rev Gastroenterol Hepatol. 2017 Jan;14(1):9-21. PubMed PMID: 27848962. PM-CID: PMC5554468. Epub 2016/11/17.eng.

  25. Andersen K, Kesper MS, Marschner JA, Konrad L, Ryu M, Kumar Vr S, Kulkarni OP, Mulay SR, Romoli S, Demleitner J, Schiller P, Dietrich A, Muller S, Gross O, Ruscheweyh HJ, Huson DH, Stecher B, Anders HJ. Intestinal dysbiosis, barrier dysfunction, and bacterial translocation account for CKD-related systemic inflammation. JASN. 2017 Jan;28(1):76-83. PubMed PMID: 27151924. PM-CID: PMC5198279. Epub 2016/05/07.eng.

  26. Spadoni I, Zagato E, Bertocchi A, Paolinelli R, Hot E, Di Sabatino A, Caprioli F, Bottiglieri L, Oldani A, Viale G, Penna G, Dejana E, Rescigno M. A gut-vascular barrier controls the systemic dissemination of bacteria. Science. 2015 Nov 13;350(6262):830-4. PubMed PMID: 26564856. Epub 2015/11/14.eng.

  27. Spadoni I, Fornasa G, Rescigno M. Organ-specific protection mediated by cooperation between vascular and epithelial barriers. Nat Rev Immunol. 2017 Dec;17(12):761-73. PubMed PMID: 28869253. Epub 2017/09/05.eng.

  28. Aron-Wisnewsky J, Gaborit B, Dutour A, Clement K. Gut microbiota and non-alcoholic fatty liver disease: New insights. Clin Microbiol Infect. 2013 Apr;19(4):338-48. PubMed PMID: 23452163. Epub 2013/03/05.eng.

  29. Wieland A, Frank DN, Harnke B, Bambha K. Systematic review: Microbial dysbiosis and nonalcoholic fatty liver disease. Alimentary Pharmacol Ther. 2015 Nov;42(9): 1051-63. PubMed PMID: 26304302. Epub 2015/08/26.eng.

  30. Sharpton SR, Yong GJM, Terrault NA, Lynch SV. Gut microbial metabolism and nonalcoholic fatty liver disease. Hepatology Comm. 2019 Jan;3(1):29-43. PubMed PMID: 30619992. PMCID: PMC6312661. Epub 2019/01/09.eng.

  31. Backhed F, Ding H, Wang T, Hooper LV, Koh GY, Nagy A, Semenkovich CF, Gordon JI. The gut microbiota as an environmental factor that regulates fat storage. Proc Natl Acad Sci U S A. 2004 Nov 2;101(44): 15718-23. PubMed PMID: 15505215. PMCID: PMC524219. Epub 2004/10/27.eng.

  32. Ridaura VK, Faith JJ, Rey FE, Cheng J, Duncan AE, Kau AL, Griffin NW, Lombard V, Henrissat B, Bain JR, Muehlbauer MJ, Ilkayeva O, Semenkovich CF, Funai K, Hayashi DK, Lyle BJ, Martini MC, Ursell LK, Clemente JC, Van Treuren W, Walters WA, Knight R, Newgard CB, Heath AC, Gordon JI. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013 Sep 6;341(6150):1241214. PubMed PMID: 24009397. PMCID: PMC3829625. Epub 2013/09/07.eng.

  33. Backhed F, Manchester JK, Semenkovich CF, Gordon JI. Mechanisms underlying the resistance to diet-induced obesity in germ-free mice. Proc Natl Acad Sci U S A. 2007 Jan 16;104(3):979-84. PubMed PMID: 17210919. PMCID: PMC1764762. Epub 2007/01/11.eng.

  34. Le Roy T, Llopis M, Lepage P, Bruneau A, Rabot S, Bevilacqua C, Martin P, Philippe C, Walker F, Bado A, Perlemuter G, Cassard-Doulcier AM, Gerard P. Intestinal microbiota determines development of non-alcoholic fatty liver disease in mice. Gut. 2013 Dec;62(12): 1787-94. PubMed PMID: 23197411. Epub 2012/12/01.eng.

  35. Moreno-Indias I, Cardona F, Tinahones FJ, Queipo-Ortuno MI. Impact of the gut microbiota on the development of obesity and type 2 diabetes mellitus. Front Microbiol. 2014;5:190. PubMed PMID: 24808896. PMCID: PMC4010744. Epub 2014/05/09.eng.

  36. Cotillard A, Kennedy SP, Kong LC, Prifti E, Pons N, Le Chatelier E, Almeida M, Quinquis B, Levenez F, Galleron N, Gougis S, Rizkalla S, Batto JM, Renault P, Dore J, Zucker JD, Clement K, Ehrlich SD. Dietary intervention impact on gut microbial gene richness. Nature. 2013 Aug 29;500(7464):585-8. PubMed PMID: 23985875. Epub 2013/08/30.eng.

  37. Le Chatelier E, Nielsen T, Qin J, Prifti E, Hildebrand F, Falony G, Almeida M, Arumugam M, Batto JM, Kennedy S, Leonard P, Li J, Burgdorf K, Grarup N, Jergensen T, Brandslund I, Nielsen HB, Juncker AS, Bertalan M, Levenez F, Pons N, Rasmussen S, Sunagawa S, Tap J, Tims S, Zoetendal EG, Brunak S, Clement K, Dore J, Kleerebezem M, Kristiansen K, Renault P, Sicheritz-Ponten T, de Vos WM, Zucker JD, Raes J, Hansen T, Bork P, Wang J, Ehrlich SD, Pedersen O. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013 Aug 29;500(7464): 541-6. PubMed PMID: 23985870. Epub 2013/08/30.eng.

  38. Karlsson FH, Tremaroli V, Nookaew I, Bergstrom G, Behre CJ, Fagerberg B, Nielsen J, Backhed F. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013 Jun 6;498(7452):99-103. PubMed PMID: 23719380. Epub 2013/05/31.eng.

  39. Qin J, Li Y, Cai Z, Li S, Zhu J, Zhang F, Liang S, Zhang W, Guan Y, Shen D, Peng Y, Zhang D, Jie Z, Wu W, Qin Y, Xue W, Li J, Han L, Lu D, Wu P, Dai Y, Sun X, Li Z, Tang A, Zhong S, Li X, Chen W, Xu R, Wang M, Feng Q, Gong M, Yu J, Zhang Y, Zhang M, Hansen T, Sanchez G, Raes J, Falony G, Okuda S, Almeida M, LeChatelier E, Renault P, Pons N, Batto JM, Zhang Z, Chen H, Yang R, Zheng W, Li S, Yang H, Wang J, Ehrlich SD, Nielsen R, Pedersen O, Kristiansen K, Wang J. A metagenome-wide association study of gut microbiota in type 2 diabetes. Nature. 2012 Oct 4;490(7418):55-60. PubMed PMID: 23023125. Epub 2012/10/02.eng.

  40. Baker SS, Baker RD. Gut microbiota and liver injury (II): Chronic liver injury. Adv Exp Med Biol. 2020;1238:39-54. PubMed PMID: 32323179. Epub 2020/04/24.eng.

  41. Boursier J, Mueller O, Barret M, Machado M, Fizanne L, Araujo-Perez F, Guy CD, Seed PC, Rawls JF, David LA, Hunault G, Oberti F, Cales P, Diehl AM. The severity of nonalcoholic fatty liver disease is associated with gut dysbiosis and shift in the metabolic function of the gut microbiota. Hepatology. 2016 Mar;63(3):764-75. PubMed PMID: 26600078. PMCID: PMC4975935. Epub 2015/11/26.eng.

  42. Zhu L, Baker SS, Gill C, Liu W, Alkhouri R, Baker RD, Gill SR. Characterization of gut microbiomes in nonalcoholic steatohepatitis (NASH) patients: A connection between endogenous alcohol and NASH. Hepatology. 2013 Feb;57(2):601-9. PubMed PMID: 23055155. Epub 2012/10/12.eng.

  43. Tripathi A, Debelius J, Brenner DA, Karin M, Loomba R, Schnabl B, Knight R. The gut-liver axis and the intersection with the microbiome. Nat Rev Gastroenterol Hepatol. 2018 Jul;15(7):397-411. PubMed PMID: 29748586. PM-CID: PMC6319369. Epub 2018/05/12.eng.

  44. Adak A, Khan MR. An insight into gut microbiota and its functionalities. CMLS. 2019 Feb;76(3):473-93. PubMed PMID: 30317530. Epub 2018/10/15.eng.

  45. Safari Z, Gerard P. The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). CMLS. 2019 Apr;76(8): 1541-58. PubMed PMID: 30683985. Epub 2019/01/27.eng.

  46. Cui Y, Wang Q, Chang R, Zhou X, Xu C. Intestinal barrier function-non-alcoholic fatty liver disease interactions and possible role of gut microbiota. J Agric Food Chem. 2019 Mar 13;67(10):2754-62. PubMed PMID: 30798598. Epub 2019/02/26.eng.

  47. Yu LX, Schwabe RF. The gut microbiome and liver cancer: Mechanisms and clinical translation. Nat Rev Gastroenterol Hepatol. 2017 Sep;14(9):527-39. PubMed PMID: 28676707. PMCID: PMC6467288. Epub 2017/07/06.eng.

  48. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, Masciana R, Forgione A, Gabrieli ML, Perotti G, Vecchio FM, Rapaccini G, Gasbarrini G, Day CP, Grieco A. Increased intestinal permeability and tight junction alterations in nonalcoholic fatty liver disease. Hepatology. 2009 Jun;49(6): 1877-87. PubMed PMID: 19291785. Epub 2009/03/18.eng.

  49. Ding Y, Yanagi K, Cheng C, Alaniz RC, Lee K, Jayaraman A. Interactions between gut microbiota and non-alcoholic liver disease: The role of microbiota-derived metabolites. Pharmacol Res. 2019 Mar; 141:521-9. PubMed PMID: 30660825. PMCID: PMC6392453. Epub 2019/01/21.eng.

  50. Cani PD, Bibiloni R, Knauf C, Waget A, Neyrinck AM, Delzenne NM, Burcelin R. Changes in gut microbiota control metabolic endotoxemia-induced inflammation in high-fat diet-induced obesity and diabetes in mice. Diabetes. 2008 Jun;57(6):1470-81. PubMed PMID: 18305141. Epub 2008/02/29.eng.

  51. Schnabl B, Brenner DA. Interactions between the intestinal microbiome and liver diseases. Gastroenterology. 2014 May;146(6): 1513-24. PubMed PMID: 24440671. PMCID: PMC3996054. Epub 2014/01/21.eng.

  52. Cho YE, Kim DK, Seo W, Gao B, Yoo SH, Song BJ. Fructose promotes leaky gut, endotoxemia, and liver fibrosis 62. through ethanol-inducible cytochrome P450-2E1-mediated oxidative and nitrative stress. Hepatology. 2019 Apr 8. PubMed PMID: 30959577. PMCID: PMC6783321. Epub 2019/04/09.eng.

  53. Tilg H, Cani PD, Mayer EA. Gut microbiome and liver diseases. Gut. 2016 Dec;65(12):2035-44. PubMed PMID: 63. 27802157. Epub 2016/11/02.eng.

  54. Hanck C, Manigold T, Bocker U, Kurimoto M, Kolbel CB, Singer MV, Rossol S. Gene expression of interleukin 18 in unstimulated peripheral blood mononuclear cells of patients with alcoholic cirrhosis. Gut. 2001 Jul;49(1):106-64. 11. PubMed PMID: 11413118. PMCID: PMC1728343. Epub 2001/06/20.eng.

  55. Volynets V, Kuper MA, Strahl S, Maier IB, Spruss A, Wagnerberger S, Konigsrainer A, Bischoff SC, Bergheim 65. I. Nutrition, intestinal permeability, and blood ethanol levels are altered in patients with nonalcoholic fatty liver disease (NAFLD). Dig Dis Sci. 2012 Jul;57(7):1932-41. PubMed PMID: 22427130. Epub 2012/03/20.eng.

  56. Zhu L, Baker RD, Baker SS. Gut microbiome and nonal-66. coholic fatty liver diseases. Pediatr Res. 2015 Jan;77(1-2):245-51. PubMed PMID: 25310763. Epub 2014/10/14. eng.

  57. Dawes EA, Foster SM. The formation of ethanol in Escherichia coli. Biochim Biophys Acta. 1956 Nov;22(2):253-67. 65. PubMed PMID: 13382840. Epub 1956/11/01.eng.

  58. Yuan J, Chen C, Cui J, Lu J, Yan C, Wei X, Zhao X, Li N, Li S, Xue G, Cheng W, Li B, Li H, Lin W, Tian C, Zhao J, Han J, An D, Zhang Q, Wei H, Zheng M, Ma X, Li W, Chen X, Zhang Z, Zeng H, Ying S, Wu J, Yang R, Liu D. Fatty 68. liver disease caused by high-alcohol-producing Klebsiella pneumoniae. Cell Metab. 2019 Oct 1;30(4):675-88.e7. PubMed PMID: 31543403. Epub 2019/09/24.eng.

  59. Rao RK. Acetaldehyde-induced barrier disruption and paracellular permeability in Caco-2 cell monolayer. Methods Mol Biol (Clifton, NJ). 2008;447:171-83. PubMed 69. PMID: 18369919. Epub 2008/03/29.eng.

  60. Arao Y, Kawai H, Kamimura K, Kobayashi T, Nakano O, Hayatsu M, Ushiki T, Terai S. Effect of methionine/choline-deficient diet and high-fat dietinduced steatohepatitis on mitochondrial homeostasis in mice. Biochem Biophys Res Commun. 2020 Jun 25;527(2):365-71. PubMed PMID: 32284169. Epub 2020/04/15.eng. 70.

  61. Hernandez GV, Smith VA, Melnyk M, Burd MA, Sprayberry KA, Edwards MS, Peterson DG, Bennet DC, Fanter RK, Columbus DA, Steibel JP, Glanz H, Immoos C, Rice MS, Santiago-Rodriguez TM, Blank J, VanderKelen JJ, Kitts CL, Piccolo BD, La Frano MR, Burrin DG, Maj M, Manjarin R. Dysregulated FXR-FGF19 signaling and choline metabolism are associated with gut dys-biosis and hyperplasia in a novel pig model of pediatric NASH. Am J Physiol Gastroint Liver Physiol. 2020 Mar 1;318(3):G582-g609. PubMed PMID: 32003601. PM-CID: PMC7099491. Epub 2020/02/01.eng.

  62. Zhu J, Wu Y, Tang Q, Leng Y, Cai W. The effects of choline on hepatic lipid metabolism, mitochondrial function and antioxidative status in human hepatic C3A cells exposed to excessive energy substrates. Nutrients. 2014 Jul 9;6(7):2552-71. PubMed PMID: 25010553. PMCID: PMC4113756. Epub 2014/07/11.eng.

  63. Sherriff JL, O'Sullivan TA, Properzi C, Oddo JL, Adams LA. Choline, its potential role in nonalcoholic fatty liver disease, and the case for human and bacterial genes. Adv Nutr (Bethesda, MD). 2016 Jan;7(1):5-13. PubMed PMID: 26773011. PMCID: PMC4717871. Epub 2016/01/17.eng.

  64. Thursby E, Juge N. Introduction to the human gut microbiota. Biochem J. 2017 May 16;474(11):1823-36. PubMed PMID: 28512250. PMCID: PMC5433529. Epub 2017/05/18.eng.

  65. Correa-Oliveira R, Fachi JL, Vieira A, Sato FT, Vinolo MA. Regulation of immune cell function by short-chain fatty acids. Clin Transl Immunol. 2016 Apr;5(4):e73. PubMed PMID: 27195116. PMCID: PMC4855267. Epub 2016/05/20.eng.

  66. Wostmann BS, Larkin C, Moriarty A, Bruckner-Kardoss E. Dietary intake, energy metabolism, and excretory losses of adult male germfree Wistar rats. Lab Animal Sci. 1983 Feb;33(1):46-50. PubMed PMID: 6834773. Epub 1983/02/01.eng.

  67. Schwiertz A, Taras D, Schafer K, Beijer S, Bos NA, Donus C, Hardt PD. Microbiota and SCFA in lean and over-weight healthy subjects. Obesity (Silver Spring, Md). 2010 Jan;18(1):190-5. PubMed PMID: 19498350. Epub 2009/06/06.eng.

  68. den Besten G, van Eunen K, Groen AK, Venema K, Reijngoud DJ, Bakker BM. The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism. J Lipid Res. 2013 Sep;54(9):2325-40. PubMed PMID: 23821742. PMCID: PMC3735932. Epub 2013/07/04.eng.

  69. den Besten G, Bleeker A, Gerding A, van Eunen K, Havinga R, van Dijk TH, Oosterveer MH, Jonker JW, Groen AK, Reijngoud DJ, Bakker BM. Short-chain fatty acids protect against high-fat diet-induced obesity via a PPARy-dependent switch from lipogenesis to fat oxidation. Diabetes. 2015 Jul;64(7):2398-408. PubMed PMID: 25695945. Epub 2015/02/20.eng.

  70. Bessone F, Razori MV, Roma MG. Molecular pathways of nonalcoholic fatty liver disease development and progression. CMLS. 2019 Jan;76(1):99-128. PubMed PMID: 30343320. Epub 2018/10/22.eng.

  71. Jin M, Lai Y, Zhao P, Shen Q, Su W, Yin Y, Zhang W. Effects of peptidoglycan on the development of steatohepatitis. Biochim Biophys Acta Mol Cell Biol Lipids. 2020 Apr;1865(4): 158595. PubMed PMID: 31953228. Epub 2020/01/19.eng.

  72. Mansouri A, Gattolliat CH, Asselah T. Mitochondrial dysfunction and signaling in chronic liver diseases. Gastroenterology. 2018 Sep;155(3):629-47. PubMed PMID: 30012333. Epub 2018/07/18.eng.

  73. Harte AL, da Silva NF, Creely SJ, McGee KC, Billyard T, Youssef-Elabd EM, Tripathi G, Ashour E, Abdalla MS, Sharada HM, Amin AI, Burt AD, Kumar S, Day CP, McTernan PG. Elevated endotoxin levels in non-alcoholic fatty liver disease. J Inflamm (London, UK). 2010 Mar 30;7:15. PubMed PMID: 20353583. PMCID: PMC2873499. Epub 2010/04/01.eng.

  74. Suk KT, Kim DJ. Gut microbiota: Novel therapeutic target for nonalcoholic fatty liver disease. Exp Rev Gastroenterol Hepatol. 2019 Mar;13(3):193-204. PubMed PMID: 30791767. Epub 2019/02/23.eng.

  75. Plovier H, Everard A, Druart C, Depommier C, Van Hul M, Geurts L, Chilloux J, Ottman N, Duparc T, Lichtenstein L, Myridakis A, Delzenne NM, Klievink J, Bhattacharjee A, van der Ark KC, Aalvink S, Martinez LO, Dumas ME, Maiter D, Loumaye A, Hermans MP, Thissen JP, Belzer C, de Vos WM, Cani PD. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nat Med. 2017 Jan;23(1):107-13. PubMed PMID: 27892954. Epub 2016/11/29.eng.

  76. Dewulf EM, Cani PD, Claus SP, Fuentes S, Puylaert PG, Neyrinck AM, Bindels LB, de Vos WM, Gibson GR, Thissen JP, Delzenne NM. Insight into the prebiotic concept: Lessons from an exploratory, double blind intervention study with inulin-type fructans in obese women. Gut. 2013 Aug;62(8): 1112-21. PubMed PMID: 23135760. PMCID: PMC3711491. Epub 2012/11/09.eng.

  77. Davis CD. The gut microbiome and its role in obesity. Nutr Today. 2016 Jul-Aug;51(4):167-74. PubMed PMID: 27795585. PMCID: PMC5082693. Epub 2016/11/01.eng.

  78. Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R, Derrien M, Druesne A, Van Hylckama Vlieg JE, Bloks VW, Groen AK, Heilig HG, Zoetendal EG, Stroes ES, de Vos WM, Hoekstra JB, Nieuwdorp M. Transfer of intestinal microbiota from lean donors inreases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology. 2012 Oct;143(4):913-6.e7. PubMed PMID: 22728514. Epub 2012/06/26.eng.

  79. Lin CH, Kohli R. Bile acid metabolism and signaling: Potential therapeutic target for nonalcoholic fatty liver disease. Clin Transl Gastroenterol. 2018 Jun 29;9(6):164. PubMed PMID: 29955036. PMCID: PMC6023895 C.H.L.

  80. Ponziani FR, Zocco MA, D'Aversa F, Pompili M, Gasbarrini A. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation. World J Gastroenterol. 2017 Jul 7;23(25):4491-9. PubMed PMID: 28740337. PMCID: PMC5504364. Epub 2017/07/26.eng.

  81. Patidar KR, Bajaj JS. Antibiotics for the treatment of hepatic encephalopathy. Metab Brain Dis. 2013 Jun;28(2):307-12. PubMed PMID: 23389621. PMCID: PMC3654040. Epub 2013/02/08.eng.

  82. Bass NM, Mullen KD, Sanyal A, Poordad F, Neff G, Leevy CB, Sigal S, Sheikh MY, Beavers K, Frederick T, Teperman L, Hillebrand D, Huang S, Merchant K, Shaw A, Bortey E, Forbes WP. Rifaximin treatment in hepatic encephalopathy. N Engl J Med. 2010 Mar 25;362(12):1071-81. PubMed PMID: 20335583. Epub 2010/03/26.eng.

  83. Scarpignato C, Pelosini I. Rifaximin, a poorly absorbed antibiotic: Pharmacology and clinical potential. Chemotherapy. 2005;51 Suppl 1:36-66. PubMed PMID: 15855748. Epub 2005/04/28.eng.

  84. Gangarapu V, Ince AT, Baysal B, Kayar Y, Killc U, Gok O, Uysal O, Senturk H. Efficacy of rifaximin on circulating endotoxins and cytokines in patients with nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2015 Jul;27(7):840-5. PubMed PMID: 26043290. Epub 2015/06/05.eng.

  85. Abdel-Razik A, Mousa N, Shabana W, Refaey M, Elzehery R, Elhelaly R, Zalata K, Abdelsalam M, Eldeeb AA, Awad M, Elgamal A, Attia A, El-Wakeel N, Eldars W. Rifaximin in nonalcoholic fatty liver disease: Hit multiple targets with a single shot. Eur J Gastroenterol Hepatol. 2018 Oct;30(10): 1237-46. PubMed PMID: 30096092. Epub 2018/08/11.eng.

  86. Bergheim I, Weber S, Vos M, Kramer S, Volynets V, Kaserouni S, McClain CJ, Bischoff SC. Antibiotics protect against fructose-induced hepatic lipid accumulation in mice: Role of endotoxin. J Hepatol. 2008 Jun;48(6): 983-92. PubMed PMID: 18395289. Epub 2008/04/09.eng.

  87. Wu WC, Zhao W, Li S. Small intestinal bacteria overgrowth decreases small intestinal motility in the NASH rats. World J Gastroenterol. 2008 Jan 14;14(2):313-7. PubMed PMID: 18186574. PMCID: PMC2675133. Epub 2008/01/12.eng.

  88. Sjolund M, Wreiber K, Andersson DI, Blaser MJ, Engstrand L. Long-term persistence of resistant Enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann Intern Med. 2003 Sep 16;139(6):483-7. PubMed PMID: 13679325. Epub 2003/09/19.eng.

  89. Jia W, Xie G, Jia W. Bile acid-microbiota crosstalk in gastrointestinal inflammation and carcinogenesis. Nat Rev Gastroenterol Hepatol. 2018 Feb;15(2):111-28. PubMed PMID: 29018272. PMCID: PMC5899973. Epub 2017/10/12.eng.

  90. Ridlon JM, Bajaj JS. The human gut sterolbiome: Bile acid-microbiome endocrine aspects and therapeutics. Acta Pharma Sin B. 2015 Mar;5(2):99-105. PubMed PMID: 26579434. PMCID: PMC4629220. Epub 2015/11/19.eng.

  91. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Disc. 2008 Aug;7(8):678-93. PubMed PMID: 18670431. Epub 2008/08/02.eng.

  92. Wahlstrom A, Sayin SI, Marschall HU, Backhed F. Intestinal crosstalk between bile acids and microbiota and its impact on host metabolism. Cell Metab. 2016 Jul 12;24(1):41-50. PubMed PMID: 27320064. Epub 2016/06/21.eng.

  93. Arab JP, Karpen SJ, Dawson PA, Arrese M, Trauner M. Bile acids and nonalcoholic fatty liver disease: Mol insights Ther Perspec. Hepatol. 2017 Jan;65(1):350-62. PubMed PMID: 27358174. PMCID: PMC5191969. Epub 2016/07/01.eng.

  94. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell. 2000 Sep 15;102(6):731-44. PubMed PMID: 11030617. Epub 2000/10/13.eng.

  95. Lu Y, Ma Z, Zhang Z, Xiong X, Wang X, Zhang H, Shi G, Xia X, Ning G, Li X. Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice. Gut. 2014 Jan;63(1):170-8. PubMed PMID: 23348961. Epub 2013/01/26.eng.

  96. Yang ZX, Shen W, Sun H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol Int. 2010 Aug 12;4(4):741-8. PubMed PMID: 21286345. PMCID: PMC2994619. Epub 2011/02/03.eng.

  97. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci U S A. 2006 Jan 24;103(4):1006-11. PubMed PMID: 16410358. PMCID: PMC1347977. Epub 2006/01/18.eng.

  98. Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res. 2010 Apr;51(4):771-84. PubMed PMID: 19783811. PMCID: PMC2842143. Epub 2009/09/29.eng.

  99. Chhabria MT, Mahajan BM. Update on patented cholesterol absorption inhibitors. Exp Opin Ther Patents. 2009 Aug;19(8): 1083-107. PubMed PMID: 19552506. Epub 2009/06/26.eng.

  100. Charlton-Menys V, Durrington PN. Human cholesterol metabolism and therapeutic molecules. Exper Physiol. 2008 Jan;93(1):27-42. PubMed PMID: 18165431. Epub 2008/01/01.eng.

  101. Miethke AG, Zhang W, Simmons J, Taylor AE, Shi T, Shanmukhappa SK, Karns R, White S, Jegga AG, Lages CS, Nkinin S, Keller BT, Setchell KD. Pharmacological inhibition of apical sodium-dependent bile acid transporter changes bile composition and blocks progression of sclerosing cholangitis in multidrug resistance 2 knockout mice. Hepatology. 2016 Feb;63(2):512-23. PubMed PMID: 26172874. PMCID: PMC4713368. Epub 2015/07/15.eng.

  102. Attia SL, Softic S, Mouzaki M. Evolving role for pharmacotherapy in NAFLD/NASH. Clin Transl Sci. 2020 Jun 25. PubMed PMID: 32583961. Epub 2020/06/26.eng.

  103. Sumida Y, Yoneda M, Ogawa Y, Yoneda M, Okanoue T, Nakajima A. Current and new pharmacotherapy options for non-alcoholic steatohepatitis. Exp Opin Pharmacother. 2020 Jun;21(8):953-67. PubMed PMID: 32237916. Epub 2020/04/03.eng.

  104. Xie C, Halegoua-DeMarzio D. Role of probiotics in non-alcoholic fatty liver disease: Does gut microbiota matter? Nutrients. 2019 Nov 19;11(11). PubMed PMID: 31752378. PMCID: PMC6893593. Epub 2019/11/23.eng.

  105. Paolella G, Mandato C, Pierri L, Poeta M, Di Stasi M, Vajro P. Gutliver axis and probiotics: Their role in non-alcoholic fatty liver disease. World J Gastroenterol. 2014 Nov 14;20(42): 15518-31. PubMed PMID: 25400436. PMCID: PMC4229517. Epub 2014/11/18.eng.

  106. Xiao MW, Lin SX, Shen ZH, Luo WW, Wang XY. Systematic review with meta-analysis: The effects of probiotics in nonalcoholic fatty liver disease. Gastroenterol Res Pract. 2019;2019:1484598. PubMed PMID: 31885541. PMCID: PMC6927028 of this paper. Epub 2019/12/31. eng.

  107. Aller R, De Luis DA, Izaola O, Conde R, Gonzalez Sagrado M, Primo D, De La Fuente B, Gonzalez J. Effect of a probiotic on liver aminotransferases in nonalcoholic fatty liver disease patients: A double blind randomized clinical trial. Eur Rev Med Pharmacol Sci. 2011 Sep;15(9):1090-5. PubMed PMID: 22013734. Epub 2011/10/22.eng.

  108. Loguercio C, Federico A, Tuccillo C, Terracciano F, D'Auria MV, De Simone C, Del Vecchio Blanco C. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol. 2005 Jul;39(6):540-3. PubMed PMID: 15942443. Epub 2005/06/09.eng.

  109. Alisi A, Bedogni G, Baviera G, Giorgio V, Porro E, Paris C, Giammaria P, Reali L, Anania F, Nobili V. Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. Alimentary Pharm Ther. 2014 Jun;39(11):1276-85. PubMed PMID: 24738701. PMCID: PMC4046270. Epub 2014/04/18.eng.

  110. Endo H, Niioka M, Kobayashi N, Tanaka M, Watanabe T. Butyrate-producing probiotics reduce nonalcoholic fatty liver disease progression in rats: New insight into the probiotics for the gut-liver axis. PLoS One. 2013;8(5):e63388. PubMed PMID: 23696823. PMCID: PMC3656030. Epub 2013/05/23.eng.

  111. Seo M, Inoue I, Tanaka M, Matsuda N, Nakano T, Awata T, Katayama S, Alpers DH, Komoda T. Clostridium butyricum MIYAIRI 588 improves high-fat diet-induced non-alcoholic fatty liver disease in rats. Dig Dis Sci. 2013 Dec;58(12): 3534-44. PubMed PMID: 24166662. Epub 2013/10/30.eng. 112. Eslamparast T, Poustchi H, Zamani F, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in nonalcoholic fatty liver disease: A randomized, double-blind, placebo-controlled pilot study. Am J Clin Nutr. 2014 Mar;99(3):535-42. PubMed PMID: 24401715. Epub 2014/01/10.eng.

  112. Karczewski J, Troost FJ, Konings I, Dekker J, Kleerebezem M, Brummer RJ, Wells JM. Regulation of human epithelial tight junction proteins by Lactobacillus plantarum in vivo and protective effects on the epithelial barrier. Am J Physiol Gastroint Liver Physiol. 2010 Jun;298(6):G851-9. PubMed PMID: 20224007. Epub 2010/03/13.eng.

  113. Gibson GR, Hutkins R, Sanders ME, Prescott SL, Reimer RA, Salminen SJ, Scott K, Stanton C, Swanson KS, Cani PD, Verbeke K, Reid G. Expert consensus document: The International Scientific Association for Probiotics and Prebiotics (ISAPP) consensus statement on the definition and scope of prebiotics. Nat Rev Gastroenterol Hepatol. 2017 Aug;14(8):491-502. PubMed PMID: 28611480. Epub 2017/06/15.eng.

  114. Parnell JA, Raman M, Rioux KP, Reimer RA. The potential role of prebiotic fibre for treatment and management of non-alcoholic fatty liver disease and associated obesity and insulin resistance. Liver Int. 2012 May;32(5):701-11. PubMed PMID: 22221818. Epub 2012/01/10.eng.

  115. Pachikian BD, Essaghir A, Demoulin JB, Catry E, Neyrinck AM, Dewulf EM, Sohet FM, Portois L, Clerbaux LA, Carpentier YA, Possemiers S, Bommer GT, Cani PD, Delzenne NM. Prebiotic approach alleviates hepatic steatosis: Implication of fatty acid oxidative and cholesterol synthesis pathways. Mol Nutr Food Res. 2013 Feb;57(2): 347-59. PubMed PMID: 23203768. Epub 2012/12/04.eng.

  116. Kok N, Roberfroid M, Delzenne N. Dietary oligofructose modifies the impact of fructose on hepatic triacylglycerol metabolism. Metabol Clin Exper. 1996 Dec;45(12):1547- 50. PubMed PMID: 8969290. Epub 1996/12/01.eng.

  117. Cani PD, Neyrinck AM, Fava F, Knauf C, Burcelin RG, Tuohy KM, Gibson GR, Delzenne NM. Selective increases of bifidobacteria in gut microflora improve high-fat-diet-induced diabetes in mice through a mechanism associated with endotoxaemia. Diabetologia. 2007 Nov;50(11):2374-83. PubMed PMID: 17823788. Epub 2007/09/08.eng.

  118. Wang Z, Xiao G, Yao Y, Guo S, Lu K, Sheng Z. The role of bifidobacteria in gut barrier function after thermal injury in rats. J Trauma. 2006 Sep;61(3):650-7. PubMed PMID: 16967002. Epub 2006/09/13.eng.

  119. Chen JJ, Wang R, Li XF, Wang RL. Bifidobacterium longum supplementation improved high-fat-fed-induced metabolic syndrome and promoted intestinal Reg I gene expression. Exp Biol Med (Maywood). 2011 Jul;236(7):823-31. PubMed PMID: 21685239. Epub 2011/06/21.eng.

  120. Kalliomaki M, Collado MC, Salminen S, Isolauri E. Early differences in fecal microbiota composition in children may predict overweight. Am J Clin Nutr. 2008 Mar;87(3):534-8. PubMed PMID: 18326589. Epub 2008/03/11.eng.

  121. Bomhof MR, Parnell JA, Ramay HR, Crotty P, Rioux KP, Probert CS, Jayakumar S, Raman M, Reimer RA. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: A pilot clinical trial. Eur J Nutr. 2019 Jun;58(4): 1735-45. PubMed PMID: 29779170. Epub 2018/05/21.eng.

  122. Zheng J, Yuan X, Cheng G, Jiao S, Feng C, Zhao X, Yin H, Du Y, Liu H. Chitosan oligosaccharides improve the disturbance in glucose metabolism and reverse the dysbiosis of gut microbiota in diabetic mice. Carbohydr Polym. 2018 Jun 15;190:77-86. PubMed PMID: 29628262. Epub 2018/04/10.eng.

  123. Zheng J, Cheng G, Li Q, Jiao S, Feng C, Zhao X, Yin H, Du Y, Liu H. Chitin oligosaccharide modulates gut microbiota and attenuates high-fat-diet-induced metabolic syndrome in mice. Marine Drugs. 2018 Feb 19; 16(2). PubMed PMID: 29463060. PMCID: PMC5852494. Epub 2018/02/22.eng.

  124. Kleessen B, Sykura B, Zunft HJ, Blaut M. Effects of inulin and lactose on fecal microflora, microbial activity, and bowel habit in elderly constipated persons. Am J Clin Nutr. 1997 May;65(5):1397-402. PubMed PMID: 9129468. Epub 1997/05/01.eng.

  125. Rivero-Gutierrez B, Gamez-Belmonte R, Suarez M, Lavin Trueba JL, Aransay A, Olivares M, Martinez O, Sanchez de Medina F, Zarzuelo A. A synbiotic composed of Lactobacillus fermentum CECT5716 and FOS prevents the development of fatty acid liver and glycemic alterations in rats fed a high fructose diet associated with changes in the microbiota. Mol Nutr Food Res. 2017 04/01;61:1600622.

  126. Yao F, Jia R, Huang H, Yu Y, Mei L, Bai L, Ding Y, Zheng P. Effect of Lactobacillus paracasei N1115 and fructool-igosaccharides in nonalcoholic fatty liver disease. Arch Med Sci. 2019 Sep;15(5): 1336-44. PubMed PMID: 31572482. PMCID: PMC6764303. Epub 2019/10/02.eng.

  127. Alves CC, Waitzberg DL, de Andrade LS, Dos Santos Aguiar L, Reis MB, Guanabara CC, Junior OA, Ribeiro DA, Sala P. Prebiotic and synbiotic modifications of beta oxidation and lipogenic gene expression after experimental hypercholesterolemia in rat liver. Front Micro- biol. 2017;8:2010. PubMed PMID: 29089934. PMCID: PMC5650986. Epub 2017/11/02.eng.

  128. Malaguarnera M, Vacante M, Antic T, Giordano M, Chisari G, Acquaviva R, Mastrojeni S, Malaguarnera G, Mistretta A, Li Volti G, Galvano F. Bifidobacterium longum with fructo-oligosaccharides in patients with nonalcoholic steatohepatitis. Dig Dis Sci. 2012 Feb;57(2):545-53. PubMed PMID: 21901256. Epub 2011/09/09.eng.

  129. Mofidi F, Poustchi H, Yari Z, Nourinayyer B, Merat S, Sharafkhah M, Malekzadeh R, Hekmatdoost A. Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: A pilot, randomised, double-blind, placebo-controlled, clinical trial. Brit J Nutr. 2017 Mar;117(5):662-8. PubMed PMID: 28345499. Epub 2017/03/28.eng.

  130. Scorletti E, Afolabi PR, Miles EA, Smith DE, Almehmadi A, Alshathry A, Childs CE, Del Fabbro S, Bilson J, Moyses HE, Clough GF, Sethi JK, Patel J, Wright M, Breen DJ, Peebles C, Darekar A, Aspinall R, Fowell AJ, Dowman JK, Nobili V, Targher G, Delzenne NM, Bindels LB, Calder PC, Byrne CD. Synbiotics alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease. Gastroenterology. 2020 May;158(6):1597-610.e7. PubMed PMID: 31987796. Epub 2020/01/29.eng.

  131. Eiseman B, Silen W, Bascom GS, Kauvar AJ. Fecal enema as an adjunct in the treatment of pseudomembranous enterocolitis. Surgery. 1958 Nov;44(5):854-9. PubMed PMID: 13592638. Epub 1958/11/01.eng.

  132. Zhou D, Pan Q, Shen F, Cao HX, Ding WJ, Chen YW, Fan JG. Total fecal microbiota transplantation alleviates highfat diet-induced steatohepatitis in mice via beneficial regulation of gut microbiota. Sci Rep. 2017 May 8;7(1):1529. PubMed PMID: 28484247. PMCID: PMC5431549. Epub 2017/05/10.eng.

  133. Bajaj JS, Kassam Z, Fagan A, Gavis EA, Liu E, Cox IJ, Kheradman R, Heuman D, Wang J, Gurry T, Williams R, Sikaroodi M, Fuchs M, Alm E, John B, Thacker LR, Riva A, Smith M, Taylor-Robinson SD, Gillevet PM. Fecal microbiota transplant from a rational stool donor improves hepatic encephalopathy: A randomized clinical trial. Hepatology. 2017 Dec;66(6): 1727-38. PubMed PMID: 28586116. PMCID: PMC6102730. Epub 2017/06/07.eng.

  134. Garcia-Lezana T, Raurell I, Bravo M, Torres-Arauz M, Salcedo MT, Santiago A, Schoenenberger A, Manichanh C, Genesca J, Martell M, Augustin S. Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis. Hepatology. 2018 Apr;67(4): 1485-98. PubMed PMID: 29113028. Epub 2017/11/08.eng.

  135. Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T, Mende DR, Li J, Xu J, Li S, Li D, Cao J, Wang B, Liang H, Zheng H, Xie Y, Tap J, Lepage P, Bertalan M, Batto JM, Hansen T, Le Paslier D, Linneberg A, Nielsen HB, Pelletier E, Renault P, Sicheritz-Ponten T, Turner K, Zhu H, Yu C, Li S, Jian M, Zhou Y, Li Y, Zhang X, Li S, Qin N, Yang H, Wang J, Brunak S, Dore J, Guarner F, Kristiansen K, Pedersen O, Parkhill J, Weissenbach J, Bork P, Ehrlich SD, Wang J. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 2010 Mar 4;464(7285):59-65. PubMed PMID: 20203603. PMCID: PMC3779803. Epub 2010/03/06. eng.

  136. Li J, Jia H, Cai X, Zhong H, Feng Q, Sunagawa S, Arumugam M, Kultima JR, Prifti E, Nielsen T, Juncker AS, Manichanh C, Chen B, Zhang W, Levenez F, Wang J, Xu X, Xiao L, Liang S, Zhang D, Zhang Z, Chen W, Zhao H, Al-Aama JY, Edris S, Yang H, Wang J, Hansen T, Nielsen HB, Brunak S, Kristiansen K, Guarner F, Pedersen O, Dore J, Ehrlich SD, Bork P, Wang J. An integrated catalog of reference genes in the human gut microbiome. Nat Biotechnol. 2014 Aug;32(8):834-41. PubMed PMID: 24997786. Epub 2014/07/07.eng.

  137. Karlsson F, Tremaroli V, Nielsen J, Backhed F. Assessing the human gut microbiota in metabolic diseases. Diabetes. 2013 Oct;62(10):3341-9. PubMed PMID: 24065795. PMCID: PMC3781439. Epub 2013/09/26.eng.

  138. Timmerman HM, Koning CJ, Mulder L, Rombouts FM, Beynen AC. Monostrain, multistrain and multispecies pro-biotics-a comparison of functionality and efficacy. Int J Food Microbiol. 2004 Nov 15;96(3):219-33. PubMed PMID: 15454313. Epub 2004/09/30.eng.

  139. Salminen S, Nybom S, Meriluoto J, Collado MC, Vesterlund S, El-Nezami H. Interaction of probiotics and pathogens-benefits to human health? Curr Opin Biotechnol. 2010 Apr;21(2):157-67. PubMed PMID: 20413293. Epub 2010/04/24.eng.

CITÉ PAR
  1. Suk Ki Tae, Koh Hong, New perspective on fecal microbiota transplantation in liver diseases, Journal of Gastroenterology and Hepatology, 37, 1, 2022. Crossref

  2. Scarpellini E., Abenavoli L., Cassano V., Rinninella E., Sorge M., Capretti F., Rasetti C., Svegliati Baroni G., Luzza F., Santori P., Sciacqua A., The Apparent Asymmetrical Relationship Between Small Bowel Bacterial Overgrowth, Endotoxemia, and Liver Steatosis and Fibrosis in Cirrhotic and Non-Cirrhotic Patients: A Single-Center Pilot Study, Frontiers in Medicine, 9, 2022. Crossref

Portail numérique Bibliothèque numérique eBooks Revues Références et comptes rendus Collections Prix et politiques d'abonnement Begell House Contactez-nous Language English 中文 Русский Português German French Spain